We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

ARKRAY

ARKRAY develops, manufactures, and distributes sample test devices, diagnostic regents, and diagnostic support tools ... read more Featured Products: More products

Download Mobile App




PT/INR Monitoring System Uses Novel Clot-Detection Technology to Deliver Results at POC

By LabMedica International staff writers
Posted on 13 Jul 2023
Print article
Image: Assure PT Care is a point-of-care test that measures the time it takes blood to clot (Photo courtesy of CoaguSense)
Image: Assure PT Care is a point-of-care test that measures the time it takes blood to clot (Photo courtesy of CoaguSense)

For precise determination of prothrombin time, medical professionals and researchers often rely on either the World Health Organization (WHO) mechanical tilt tube technique or the Fibrometer. Both methods utilize a mechanical process to directly identify clot formation but can be complex to perform. Now, an advanced PT/INR Monitoring System marks a significant breakthrough in point-of-care prothrombin time monitoring technology, thanks to its miniaturization and simplification of the direct mechanical clot detection process.

ARKRAY USA, Inc. (Kyoto, Japan), in a strategic partnership with CoaguSense, Inc. (Fremont, CA, USA), has launched the Assure PT Care PT/INR Monitoring System. ARKRAY USA is the sole distributor of Assure PT Care, a point-of-care test that measures the clotting time of blood utilizing a patented micromechanical system. The system's results are comparable to those of the gold-standard WHO tilt-tube method and are reported in PT seconds and INR with the highest levels of accuracy and precision. Instant results are crucial for effectively monitoring patients on anticoagulation therapy, enabling optimal care decisions. The Assure PT Care system, which is wireless, enhances operational efficiency for PT/INR testing and offers immediate results, facilitating prompt treatment decisions. It is certified for professional use in a CLIA-waived setting and offers the benefits of being compact and easy to use.

"ARKRAY is committed to offering reliable and cost-effective solutions to our long-term care customers," said Tadashi Inoue, Chief Executive Officer of ARKRAY USA. "We are excited to broaden and diversify our product offering with Assure PT Care to continue serving our customers with a brand they know and trust for reliability, quality, and excellent service."

Related Links:
ARKRAY USA, Inc. 
CoaguSense, Inc. 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: Microscopic images showing healthy villi on the left and diseased villi on the right (Photo courtesy of Florian Jaeckle/University of Cambridge)

Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy

Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.